ABSTRACT
BACKGROUND: Recessive dystrophic epidermolysis bullosa (RDEB) is associated with a high mortality rate due to the development of life-threatening, metastatic cutaneous squamous cell carcinoma (cSCC). Elevated transforming growth factor-beta (TGF-ß) signalling is implicated in cSCC development and progression in patients with RDEB. OBJECTIVES: To determine the effect of exogenous and endogenous TGF-ß signalling in RDEB cSCC with a view to assessing the potential of targeting TGF-ß signalling for RDEB cSCC therapy. METHODS: A panel of 11 patient-derived RDEB cSCC primary tumour keratinocyte cell lines (SCCRDEBs) were tested for their signalling and proliferation responses to exogenous TGF-ß. Their responses to TGF-ß receptor type-1 (TGFBR1) kinase inhibitors [SB-431542 and AZ12601011 (AZA01)] were tested using in vitro proliferation, clonogenicity, migration and three-dimensional invasion assays, and in vivo tumour xenograft assays. RESULTS: All SCCRDEBs responded to exogenous TGF-ß by activation of canonical SMAD signalling and proliferative arrest. Blocking endogenous signalling by treatment with SB-431542 and AZ12601011 significantly inhibited proliferation (seven of 11), clonogenicity (six of 11), migration (eight of 11) and invasion (six of 11) of SCCRDEBs. However, these TGFBR1 kinase inhibitors also promoted proliferation and clonogenicity in two of 11 SCCRDEB cell lines. Pretreatment of in vitro TGFBR1-addicted SCCRDEB70 cells with SB-431542 enhanced overall survival and reduced tumour volume in subcutaneous xenografts but had no effect on nonaddicted SCCRDEB2 cells in these assays. CONCLUSIONS: Targeting TGFBR1 kinase activity may have therapeutic benefit in the majority of RDEB cSCCs. However, the potential tumour suppressive role of TGF-ß signalling in a subset of RDEB cSCCs necessitates biomarker identification to enable patient stratification before clinical intervention.
Subject(s)
Carcinoma, Squamous Cell , Epidermolysis Bullosa Dystrophica , Skin Neoplasms , Humans , Transforming Growth Factor beta , Transforming Growth FactorsABSTRACT
Recessive dystrophic epidermolysis bullosa (RDEB; OMIM #226600) is one of the most devastating subtypes of epidermolysis bullosa, a group of skin and mucous membrane blistering disorders often associated with extracutaneous manifestations. RDEB is caused by mutations in COL7A1, the gene encoding type VII collagen (C7), and to date over 700 different mutations in the 8835 nucleotides constituting the open reading frame or adjacent exon-intron boundaries of COL7A1 have been described. We used targeted next-generation sequencing to identify seven previously unreported mutations in a cohort of 17 Mexican patients who were diagnosed with RDEB based on clinical presentation and immunoepitope mapping. Our study expands the spectrum of mutations identified in this cohort, including those suitable for emerging therapies reliant on precise genotyping.
Subject(s)
Collagen Type VII/genetics , Epidermolysis Bullosa Dystrophica/genetics , High-Throughput Nucleotide Sequencing , Humans , Mexico , MutationABSTRACT
This article summarizes recommendations reached following a systematic literature review and expert consensus on the diagnosis and management of cutaneous squamous cell carcinomas in people with epidermolysis bullosa. The guidelines are intended to help inform decision making by clinicians dealing with this complex complication of a devastating disease.
Subject(s)
Carcinoma, Squamous Cell/therapy , Epidermolysis Bullosa/complications , Skin Neoplasms/therapy , Amputation, Surgical/methods , Artificial Limbs , Carcinoma, Squamous Cell/diagnosis , Carcinoma, Squamous Cell/prevention & control , Consensus , Humans , Lymphatic Metastasis , Minimally Invasive Surgical Procedures/methods , Neoplasm Metastasis , Neoplasm Staging , Pain/prevention & control , Practice Guidelines as Topic , Psychotherapy/methods , Retinoids/therapeutic use , Sentinel Lymph Node Biopsy/methods , Skin Neoplasms/diagnosis , Skin Neoplasms/prevention & control , Terminal Care/methods , Wound Closure TechniquesSubject(s)
Ainhum/genetics , Constriction, Pathologic/genetics , Keratoderma, Palmoplantar/genetics , Mutation, Missense/genetics , TRPV Cation Channels/genetics , Administration, Topical , Adult , Ainhum/diagnosis , Ainhum/pathology , Biopsy , Constriction, Pathologic/diagnosis , Constriction, Pathologic/pathology , Cuba/epidemiology , Female , Humans , Keratoderma, Palmoplantar/diagnosis , Keratoderma, Palmoplantar/drug therapy , Keratoderma, Palmoplantar/pathology , Lactic Acid/administration & dosage , Lactic Acid/therapeutic use , Pedigree , TRPV Cation Channels/metabolism , Urea/administration & dosage , Urea/therapeutic useABSTRACT
BACKGROUND: Epidermolysis bullosa is a group of inherited skin fragility diseases varying in severity from mild scarring to infant mortality. Great efforts are being undertaken to develop therapeutic strategies to treat the more pernicious forms of this disease, particularly those associated with recessive, loss-of-function mutations. In such cases significant effort is directed toward delivering recombinant protein at levels sufficient to demonstrate clinical benefit. Recessive dystrophic epidermolysis bullosa (RDEB) predisposes patients to a high incidence of life-threatening cutaneous squamous cell carcinoma (cSCC). Mutations in the gene encoding type VII collagen, COL7A1, are the sole cause of this disease and conflicting reports concerning type VII collagen and COL7A1 in carcinogenesis exist. OBJECTIVES: To investigate potential oncogenic effects of expressing recombinant type VII collagen in patient cells. METHODS: We used retroviral transduction to introduce type VII collagen into keratinocytes derived from patients with and without RDEB. RESULTS: Retroviral expression of type VII collagen in cSCC keratinocytes established from patients with RDEB resulted in increased cell adhesion, migration and invasion coupled with a concurrent increase in PI3K and MAPK signalling. CONCLUSIONS: Our data suggest caution when formulating strategies where delivery of type VII collagen is likely to exceed levels seen under normal physiological conditions in a patient group with a higher inherent risk of developing skin cancer.
Subject(s)
Carcinoma, Squamous Cell/enzymology , Collagen Type VII/metabolism , Epidermolysis Bullosa Dystrophica/enzymology , Mitogen-Activated Protein Kinase Kinases/metabolism , Phosphatidylinositol 3-Kinases/metabolism , Skin Neoplasms/enzymology , Carcinoma, Squamous Cell/genetics , Carcinoma, Squamous Cell/pathology , Cell Adhesion/drug effects , Cell Adhesion/physiology , Cell Movement/drug effects , Cell Movement/physiology , Cells, Cultured , Collagen Type VII/genetics , Collagen Type VII/pharmacology , Epidermolysis Bullosa Dystrophica/genetics , Epidermolysis Bullosa Dystrophica/pathology , Gene Knockdown Techniques/methods , Humans , Keratinocytes/enzymology , MAP Kinase Signaling System/physiology , Neoplasm Invasiveness , RNA, Small Interfering/pharmacology , Recombinant Proteins/pharmacology , Skin Neoplasms/genetics , Skin Neoplasms/pathology , TransfectionSubject(s)
Collagen Type VII/genetics , Epidermolysis Bullosa Dystrophica/genetics , Skin Diseases, Vesiculobullous/genetics , Adult , Blister/pathology , Child , DNA Mutational Analysis , Epidermolysis Bullosa Dystrophica/blood , Epidermolysis Bullosa Dystrophica/pathology , Female , Genes, Recessive , Humans , Male , Mutation , Peru/epidemiology , Polymorphism, Single Nucleotide/genetics , Skin Diseases, Vesiculobullous/pathologyABSTRACT
Leprosy is a chronic granulomatous disease caused by the bacillus Mycobacterium leprae. It primarily affects the skin and peripheral nerves and is still endemic in various regions of the world. Clinical presentation depends on the patient's immune status at the time of infection and during the course of the disease. Leprosy is associated with disability and marginalization. Diagnosis is clinical and is made when the patient has at least 1 of the following cardinal signs specified by the World Health Organization: hypopigmented or erythematous macules with sensory loss; thickened peripheral nerves; or positive acid-fast skin smear or skin biopsy with loss of adnexa at affected sites. Leprosy is treated with a multidrug combination of rifampicin, clofazimine, and dapsone. Two main regimens are used depending on whether the patient has paucibacillary or multibacillary disease.
Subject(s)
Leprosy , Antibodies, Bacterial/blood , Antibodies, Bacterial/immunology , Antigens, Bacterial/immunology , BCG Vaccine , Bacterial Vaccines , Drug Therapy, Combination , Global Health , Glycolipids/immunology , Humans , Intradermal Tests , Lepromin , Leprostatic Agents/administration & dosage , Leprostatic Agents/adverse effects , Leprostatic Agents/therapeutic use , Leprosy/classification , Leprosy/diagnosis , Leprosy/drug therapy , Leprosy/epidemiology , Leprosy/microbiology , Mycobacterium leprae/immunology , Mycobacterium leprae/isolation & purification , Mycobacterium leprae/physiology , Serologic Tests/methods , Skin/microbiology , Skin/pathology , Species SpecificityABSTRACT
The tools for diagnosis of epidermolysis bullosa have advanced greatly since Hintner's group introduced antigen mapping as a diagnostic test for this family of genodermatoses. Monoclonal or polyclonal antibodies raised against some of the specific proteins found in the epidermis and basement membrane of the epidermis have allowed 4 types of epidermolysis bullosa de be identified and all variants to be classified. When a newborn baby presents with blisters, many conditions are implicated in the differential diagnosis. Examination under an optical microscope can suggest epidermolysis bullosa, but immunofluorescence mapping and electron microscopy are required for confirmation of the diagnosis and further classification of congenital epidermolysis bullosa. This article explains the importance of immunofluorescence antigen mapping and describes the methods employed for classification and subclassification of epidermolysis bullosa.
Subject(s)
Epidermolysis Bullosa/diagnosis , Fluorescent Antibody Technique, Direct , Basement Membrane/immunology , Biopsy , Diagnosis, Differential , Epidermis/immunology , Epidermis/ultrastructure , Epidermolysis Bullosa/classification , Epidermolysis Bullosa/immunology , Epidermolysis Bullosa/pathology , Epidermolysis Bullosa Dystrophica/diagnosis , Epidermolysis Bullosa Dystrophica/immunology , Epidermolysis Bullosa Dystrophica/pathology , Epidermolysis Bullosa Simplex/diagnosis , Epidermolysis Bullosa Simplex/immunology , Epidermolysis Bullosa Simplex/pathology , Epidermolysis Bullosa, Junctional/diagnosis , Epidermolysis Bullosa, Junctional/immunology , Epidermolysis Bullosa, Junctional/pathology , Humans , Infant, Newborn , Microscopy, Fluorescence , Specimen HandlingSubject(s)
Drug Eruptions/etiology , Linear IgA Bullous Dermatosis/etiology , Female , Humans , MaleABSTRACT
A pair of 2-year-old female monozygotic twins presented with short and brittle hair. There was marked reduction in hair density, and excessive curving of the eyelashes. Onychodystrophy was also evident. They also had developmental delay in verbal and motor skills. Neither their parents nor other relatives were known to be affected, and there was no history of consanguinity. Examination of the hair shaft under light microscopy showed trichoschisis, which was more evident under electron microscopy. Under polarized light, the hair shafts showed the pathognomonic 'tiger-tail' pattern. The level of sulphur in the hair was low. Both patients were negative for TTDN1 mutation. Clinical correlation was performed and the diagnosis of Sabinas syndrome was made. Sabinas syndrome is a very rare autosomal recessive disorder first described in a group of patients from a small community in north-eastern Mexico. It is diagnosable at birth, and its major symptoms include brittle hair, mental retardation and nail dysplasia. Structural hair abnormalities are seen by both light and electron microscopy.
Subject(s)
Diseases in Twins/diagnosis , Trichothiodystrophy Syndromes/diagnosis , Child, Preschool , Diseases in Twins/pathology , Female , Hair/ultrastructure , Humans , Trichothiodystrophy Syndromes/classification , Trichothiodystrophy Syndromes/pathology , Twins, MonozygoticABSTRACT
BACKGROUND: The identification of the molecular basis of disorders of keratinisation has significantly advanced our understanding of skin biology, revealing new information on key structures in the skin, such as the intermediate filaments, desmosomes, and gap junctions. Among these disorders, there is an extraordinarily heterogeneous group known as palmoplantar keratodermas (PPK), for which only a few molecular defects have been described. A particular form of PPK, known as punctate PPK, has been described in a few large autosomal dominant pedigrees, but its genetic basis has yet to be identified. AIM: Identification of the gene for punctate PPK. METHODS: Clinical examination and linkage analysis in three families with punctate PPK. RESULTS: A genomewide scan was performed on an extended autosomal dominant pedigree, and linkage to chromosome 15q22-q24 was identified. With the addition of two new families with the same phenotype, we confirmed the mapping of the locus for punctate PPK to a 9.98 cM interval, flanked by markers D15S534 and D15S818 (maximum two point lod score of 4.93 at theta = 0 for marker D15S988). CONCLUSIONS: We report the clinical and genetic findings in three pedigrees with the punctate form of PPK. We have mapped a genetic locus for this phenotype to chromosome 15q22-q24, which indicates the identification of a new gene involved in skin integrity.
Subject(s)
Chromosomes, Human, Pair 15 , Keratoderma, Palmoplantar/genetics , Chromosome Mapping , Female , Humans , Keratoderma, Palmoplantar/pathology , Male , Pedigree , PhenotypeABSTRACT
BACKGROUND: Gingival lesions in patients with dystrophic epidermolysis bullosa (DEB) are a common manifestation. However, their clinical features, frequency and severity are currently unknown. METHODS: Forty-five DEB patients were assessed by an oral medicine specialist, who analysed the presence/absence of four clinical signs (erythema, erosion/ulcer, atrophy, blister) on free and attached gingiva, using the Epidermolysis Bullosa Oropharyngeal Severity score. RESULTS: Twenty-eight (62.2%) out of 45 DEB patients showed different types of gingival lesions, whose presence/absence and total frequency/distribution were not significantly different between males and females (p=0.087 and p=0.091, respectively). Erythema was the most prevalent lesion (66.2%) and the recessive DEB severe generalized (RDEB-sev gen) reached the highest median disease activity score. A significant correlation was observed between the DEB subtypes and the disease activity median score (p<0.001), but not between age and total disease activity score in each group of DEB (p>0.05). Lastly, logistic regression showed that only gender (p=0.031) and RDEB-sev gen (p=0.001) were risks factors for the presence of gingival lesions. CONCLUSIONS: Gingival lesions in DEB patients are a relatively common entity and may have multiple clinical aspects, emphasizing the need for thorough attention and awareness among dentists.
Subject(s)
Epidermolysis Bullosa Dystrophica/pathology , Gingival Diseases/pathology , Adolescent , Adult , Blister/pathology , Child , Child, Preschool , Cross-Sectional Studies , Epidermolysis Bullosa Dystrophica/classification , Erythema/pathology , Female , Gingival Diseases/classification , Humans , Infant , Male , Middle Aged , Oral Ulcer/pathology , Periodontal Atrophy/pathology , Prevalence , Risk Factors , Sex Factors , Young AdultABSTRACT
Non-sense mutations on both alleles of either the type VII collagen gene (COL7A1) or the genes encoding laminin 5 (LAMA3, LAMB3, or LAMC2) usually result in clinically severe forms of recessive dystrophic or junctional epidermolysis bullosa, respectively. In this study we assessed two unrelated families whose mutations in genomic DNA predicted severe recessive dystrophic epidermolysis bullosa or junctional epidermolysis bullosa phenotypes but in whom the manifestations were milder than expected. The recessive dystrophic epidermolysis bullosa patients had a homozygous single base-pair frameshift mutation in exon 19 of COL7A1 (2470insG). Clinically, there was generalized blistering but only mild scarring. Skin biopsy revealed positive type VII collagen immunoreactivity and recognizable anchoring fibrils. The junctional epidermolysis bullosa patients were compound heterozygotes for a frameshift/non-sense combination of mutations in exons 3 and 17 of LAMB3 (29insC/Q834X). These patients did not have the lethal form of junctional epidermolysis bullosa but, as adults, displayed the milder generalized atrophic benign epidermolysis bullosa variant. There was undetectable laminin 5 staining at the dermal-epidermal junction using an antibody to the beta3 chain, but faintly positive alpha3 and gamma2 chain labeling, and there was variable hypoplasia of hemidesmosomes. To explain the milder recessive dystrophic epidermolysis bullosa and junctional epidermolysis bullosa phenotypes in these families, reverse transcription-polymerase chain reaction, using RNA extracted from frozen skin, was able to provide evidence for some rescue of mutant mRNA transcripts with restoration of the open- reading frame. In the recessive dystrophic epidermolysis bullosa patients, transcripts containing in-frame skipping of exon 19 of COL7A1 in the cDNA were detected, and in the junctional epidermolysis bullosa patients transcripts with in-frame skipping of exon 17 of LAMB3 were identified. The truncated proteins encoded by these transcripts are expected to lack certain critical domains involved in cell-matrix attachment, but may still be able to contribute to adhesion thereby moderating the severity of the skin blistering. This study shows the limitations in predicting phenotype in epidermolysis bullosa solely based on mutation analysis of genomic DNA and emphasizes the importance of immunohistochemistry, electron microscopy, and mRNA assessment as parallel investigations.
Subject(s)
Cell Adhesion Molecules/genetics , Collagen/genetics , Epidermolysis Bullosa Dystrophica/genetics , Epidermolysis Bullosa, Junctional/genetics , Exons , Frameshift Mutation , Mutation , Adolescent , Adult , Desmosomes/ultrastructure , Female , Fluorescent Antibody Technique , Humans , Microscopy, Electron , Phenotype , Reverse Transcriptase Polymerase Chain Reaction , Skin/ultrastructure , KalininABSTRACT
The inherited mechanobullous disease, dystrophic epidermolysis bullosa, is caused by type VII collagen gene (COL7A1) mutations. We studied six unrelated patients with a distinct clinical subtype of this disease, epidermolysis bullosa pruriginosa, characterized by pruritus, excoriated prurigo nodules, and skin fragility. Mutation analysis using polymerase chain reaction amplification of genomic DNA, heteroduplex analysis and direct nucleotide sequencing demonstrated pathogenetic COL7A1 mutations in each case. Four patients had a glycine substitution mutation on one COL7A1 allele (G1791E, G2242R, G2369S, and G2713R), a fifth was a compound heterozygote for a splice site mutation (5532 + 1G-to-A) and a single base pair deletion (7786delG), and a sixth patient was heterozygous for an out-of-frame deletion mutation (6863del16). This study shows that the molecular pathology in patients with the distinctive clinical features of epidermolysis bullosa pruriginosa is heterogeneous and suggests that other factors, in addition to the inherent COL7A1 mutation(s), may be responsible for an epidermolysis bullosa pruriginosa phenotype.
Subject(s)
Collagen/genetics , Epidermolysis Bullosa Dystrophica/genetics , Adolescent , Adult , Alleles , Base Pairing , Exons , Female , Genetic Heterogeneity , Genotype , Humans , Male , Mutation , Point Mutation , Polymerase Chain Reaction , Pruritus/genetics , Restriction MappingABSTRACT
Previous investigations have attempted to correlate the genotype with the cutaneous phenotype in patients with epidermolysis bullosa (EB), but never with the oropharyngeal phenotype. Seventeen dystrophic EB (DEB) patients were genotyped for COL7A1 gene mutations and divided into five distinct groups. Oropharyngeal disease severity was assessed with the Epidermolysis Bullosa Oropharyngeal Severity (EBOS) score by an oral medicine specialist. The genotype-phenotype correlation was calculated by Kruskal-Wallis analysis of variance using the Mann-Whitney test, applying the Bonferroni correction. The most severe oropharyngeal phenotype was found in the group with the 2470insG/3948insT mutation, with a mean disease severity score of 18.50 ± 2.12; the mildest was found in the 6862del16 mutation group, with a mean disease severity score of 0.57 ± 1.13. The most significant difference in median score was found in the total score (P = 0.009), followed by tongue (P = 0.02) and upper lip (P = 0.021), but no correlation was found between disease severity and the groups (P>0.005, after Bonferroni correction). Multiple comparisons among the five different genotypic groups revealed no statistically significant genotype-oropharyngeal phenotype correlation; it was not possible to establish which group was more severe, or to associate a specific mutation to a specific oropharyngeal phenotype.
Subject(s)
Collagen Type VII/genetics , Epidermolysis Bullosa Dystrophica/genetics , Mouth Diseases/genetics , Adult , Child, Preschool , Female , Genotype , Humans , Infant , Male , Mexico , Middle Aged , Mutation , Phenotype , Retrospective Studies , Severity of Illness IndexABSTRACT
Epidermolysis bullosa is a group of hereditary diseases affecting 1 in 17,000 live births worldwide. It consists of blistering of the skin and mucous membranes in response to minimal trauma. The disorder seriously affects the patient's quality of life. Diagnosis is based on immunofluorescence mapping and electron microscopy. Treatment is symptomatic, although new cellular and molecular therapies are currently under investigation. This review covers aspects of the molecular biology, clinical presentation, diagnosis, and treatment of epidermolysis bullosa relevant to improving the care for affected patients.
Subject(s)
Epidermolysis Bullosa , Epidermolysis Bullosa/diagnosis , Epidermolysis Bullosa/therapy , HumansABSTRACT
BACKGROUND: Type VII collagen gene (COL7A1) mutations are the cause of dystrophic epidermolysis bullosa (DEB), but most mutations are specific to individual families, and there are limited data on the nature of COL7A1 mutations in certain ethnic populations. OBJECTIVE: To determine the molecular basis of DEB in Hispanic Mexican patients. METHODS: Patients were recruited through a newly established support group, Fundacion DEBRA Mexico. Molecular analysis was performed by polymerase chain reaction (PCR) of genomic DNA using COL7A1-specific primers, heteroduplex analysis, and direct nucleotide sequencing. RESULTS: Fifty-nine of a possible 67 COL7A1 mutations (88%) were identified in 36 affected individuals (31 recessive, five dominant) in 21 families. Recessive mutations included six frameshift mutations, four silent glycine substitutions, and two splice-site mutations. Dominant mutations comprised a de novo glycine substitution and an internal deletion. Conclusions This study establishes the molecular basis of DEB in a group of Mexican patients. Only two of the mutations have been identified previously in other ethnic groups; the remainder are specific to this population. These new data are helpful in facilitating the accurate diagnosis of DEB subtype, in improving genetic counseling, and in providing further insight into the pathophysiology of this mechanobullous disease.
Subject(s)
Collagen/genetics , Epidermolysis Bullosa Dystrophica/genetics , Foot Dermatoses/genetics , Hand Dermatoses/genetics , White People/genetics , Adolescent , Adult , Child, Preschool , DNA Primers , Epidermolysis Bullosa Dystrophica/pathology , Female , Foot Dermatoses/pathology , Hand Dermatoses/pathology , Humans , Knee/pathology , Male , Mexico , Mutation , Polymerase Chain ReactionABSTRACT
A 32-basepair deletion polymorphism in the CCR5 chemokine receptor gene (DeltaCCR5) has recently been identified and shown to have functional significance in determining susceptibility to infection by human immunodeficiency virus type 1 (HIV-1) and a possible influence on disease progression in HIV-1-positive individuals. Interest has also focused on the geographical distribution of the DeltaCCR5 allele, particularly in considering epidemiological aspects of HIV disease and its impact on health economics. In this report we have assessed the frequency of the DeltaCCR5 allele in a Hispanic Mexican population and found a gene frequency of 4.4% in 103 individuals. The DeltaCCR5 allele is not present in indigenous Mexican populations but is present in about 8% of the population in Spain. Gene flow from the European gene pool consistent with Mexico's colonial past would account for the findings in this study.